Therefore, our data suggest that although amyloidosis on its own may not cause elevated plasma GFAP in mice, combining amyloidosis with factors that reduce vascular resilience, such as apoA-I deficiency, may better recapitulate changes in plasma GFAP observed in human AD subjects. Here, GFAP is linked to Alzheimer disease.